Skip to main content

Meisner Lara's Form 4 filing

Viridian Therapeutics, Inc.DEVRDN · filed Dec 19, 2022

Accession no.
0000899243-22-039056
Filed
Dec 19, 2022
Trade date
Dec 15-16, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $45.3K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Meisner LaraCIK 0001883986Officer (General Counsel and Secretary)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 15, 2022Common StockMOption exerciseAcquired+300$23.03+$6,909300Direct
Dec 15, 2022Common StockSSaleDisposed−300$28.08F1−$8,4240Direct
Dec 16, 2022Common StockMOption exerciseAcquired+1,297$23.03+$29,869.911,297Direct
Dec 16, 2022Common StockSSaleDisposed−1,297$28.44F2−$36,886.680Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 15, 2022Common StockMOption exerciseDisposed−300$0.00$062,944Direct
Dec 16, 2022Common StockMOption exerciseDisposed−1,297$0.00$061,647Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F2

This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.72. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)